Drug research

Coversin

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as rEV576; rVA576

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862	AKARI Therapeutics	Phase 2	Completed	2018-03-20Actual
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsNCT03427060	AKARI Therapeutics	Phase 2	Completed	2018-11-15Actual

AKARI TherapeuticsCompletedPrimary completion: 2018-03-20 · Actual

Trial details

AKARI TherapeuticsCompletedPrimary completion: 2018-11-15 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.